FDA Eases HRT Warning Labels for Women, Reframing Menopause Care After 20 Years
Updated
Updated · AARP · Jun 10
FDA Eases HRT Warning Labels for Women, Reframing Menopause Care After 20 Years
3 articles · Updated · AARP · Jun 10
Summary
Updated FDA labeling has removed broad black box warnings from some menopausal hormone therapies, reopening discussions that many women had avoided for more than 20 years.
Newer research found risks vary sharply by age, health status, hormone type and when treatment begins, rather than applying uniformly to all women.
Within 10 years of a woman’s last menstrual period is now seen as the key treatment window, when symptom relief may be greatest and risks lower than for women starting decades later.
The shift does not make HRT universally appropriate; clinicians still weigh breast cancer, stroke and cardiovascular risks against benefits for hot flashes, sleep disruption, mood changes and vaginal discomfort.
Is there a 'golden decade' after menopause to maximize HRT benefits and minimize risks?
Why is the once-feared hormone therapy now being called a key to healthy aging?
FDA Removes Black Box Warning from Estrogen HRT in 2025: A Landmark Shift in Menopause Care and Women's Health Policy
Overview
In November 2025, the FDA made a major policy change by removing the long-standing black box warning from estrogen-containing hormone replacement therapy (HRT) products. This warning had strongly shaped how HRT was viewed and used for years. The decision followed a careful re-evaluation of scientific evidence, recognizing the important role of estrogen in women's health. By lifting the warning, the FDA aimed to reduce fear, encourage open discussions between patients and doctors, and support more personalized treatment options for women considering HRT. This marks a significant shift in menopause care and women's health policy.